The current CE-mark applies to the professional use of the test platform Egoo.Health for sale on the European market.
Qlife will not respond to preliminary rejection by the Danish Medicines Agency for COVID-19 test – focus on receiving CE-marking by year-end
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for the company’s COVID-19 test. The company has since had 14 days to respond to the preliminary announcement and now the company has decided to waive this. Instead, Qlife will focus on completing the documentation for CE-marking in accordance with the timeline previously communicated. Qlife expects CE-marking at the turn of the year 2020/2021.
Qlife expects to CE mark its COVID-19 test for professional use in the Egoo.Health system within short.
Since May 2020, Qlife has been handling all testing for COVID-19 for professional football in Denmark.
On November 13, Qlife was informed that the Danish Medicines Agency (Lægemiddelstyrelsen) had rejected the application for temporay approval in Denmark “in the interest of health protection” for th
”We will do our utmost to protect the participating players against the coronavirus”, says Frank Smith, Covid-19 Officer, European Handball Federation Euro 2020 “It requires testing with high preci
Resolution on (A) employee option program; and (B) directed issue of warrants and approval of transfer of warrants
FINANCIAL SUMMARY - THIRD QUARTER 2020
In parallel to the ongoing process of preparing and putting together the dossier for the CE-mark, Qlife has submitted an application for placing the product on the market at this stage, as it offer
The Nomination Committee consists of the following persons, who together represent approximately 39 percent of the company's shares and votes.